Fused Tetracyclic Staining Agents for Non-Intercalating Nucleic Acid Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid staining agents, such as SYBR, suffer from limitations including false positive signals, lack of sensitivity, toxicity, and inability to detect single-strand DNA, RNA, and proteins without interfering with DNA mobility.
Innovation Solution
Development of fused tetracyclic, heterocyclic compounds that act as non-intercalating nucleic acid staining agents, capable of binding to dsDNA, ssDNA, RNA, and proteins, while ensuring safety, sensitivity, and cost-effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If Ethidium Bromide is used as a staining agent, then sensitivity and DNA binding capability are improved, but mutagenicity and genotoxicity increase
Solution Approach 1:
The patent develops new fused tetracyclic staining agents that replace harmful established dyes like Ethidium Bromide. These new compounds provide comparable or superior detection sensitivity without the mutagenic properties, effectively creating a safe alternative that can be used without concern for genetic damage to specimens or researchers.
Solution Approach 2:
The invention modifies the chemical structure by using fused tetracyclic heterocyclic frameworks with specific substituents (halogens, hydroxyl groups, alkoxy groups) to alter the binding properties and fluorescence characteristics while eliminating the toxic effects of traditional stains. This structural parameter change achieves both high sensitivity and safety.
2Reliability
If SYBR Green is used as a staining agent, then safety and sensitivity are improved compared to Ethidium Bromide, but false positive results and limited applicability to dsDNA only occur
Solution Approach 1:
The patent designs fused tetracyclic compounds with versatile binding capabilities that work across multiple nucleic acid types (dsDNA, ssDNA, RNA) and protein targets. The molecular structure incorporates features that enable interaction with various biomolecules, making a single staining agent applicable to diverse diagnostic needs without false positives.
Solution Approach 2:
The invention introduces specific functional groups at different positions of the fused tetracyclic core (such as hydroxyl groups at positions 3 and 10, alkoxy groups at positions 2 and 7) to create localized binding sites with different affinities, enabling the single compound to interact selectively with different nucleic acid structures and proteins.
3Measurement precision
If intercalating dyes are used for staining, then binding affinity is improved, but DNA mobility and electrophoresis accuracy are worsened
Solution Approach 1:
The patent employs fused tetracyclic compounds as intermediary binding agents that attach to nucleic acids through external groove binding rather than intercalation. This intermediary mechanism provides sufficient binding affinity for detection while maintaining DNA structural integrity and natural mobility during electrophoresis, avoiding the artifacts caused by intercalating dyes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed staining agents provide faster, accurate, and sensitive detection of nucleic acids, are non-toxic, and do not interfere with DNA mobility, making them suitable for various diagnostic applications.
Implementation Method 1
The proposed staining agents provide faster, accurate, and sensitive detection of nucleic acids... capable of binding to dsDNA, ssDNA, RNA, and proteins
Data Source
AI summary
The present invention discloses methods of preparation of fluorescent nucleic acid staining agents containing fused tetracyclic, heterocyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, solvates, and their applications in the detection of nucleic acids, and assay methods to establish the efficacy of the nucleic acid staining agents as given in formula (I)